Roche's petrelintide showed benefits but early results show inferior benefits over Lilly's eloralintide | iPharmaCenter

Roche reported encouraging mid‑stage results for petrelintide, a once‑weekly amylin analogue being developed as a novel option for people with overweight and obesity. In the 42‑week ZUPREME‑1 trial, which enrolled 493 adults with a mean BMI of about 37 kg/m² on background diet and exercise, all five petrelintide dose regimens achieved statistically significant and clinically meaningful weight loss versus placebo at week 28, meeting the primary endpoint.

Weight reduction continued beyond the primary analysis, with the most effective dose delivering an average 10.7% loss from baseline at week 42 compared with 1.7% for placebo, and nearly all participants in that cohort successfully titrating to and remaining on the maintenance dose, underscoring a tolerability profile that closely resembled placebo.

ZUPREME‑1 used a classic obesity trial framework, with a screening phase, gradual up‑titration over up to 16 weeks, and a maintenance period out to week 42, plus nine weeks of follow‑up, and captured a broad cardiometabolic read‑out including waist circumference, HbA1c, hsCRP, fasting lipids, fasting glucose, and MRI‑based body composition as secondary and exploratory endpoints. These Phase II findings will guide dose selection and population targeting for Phase III, while a companion Phase II trial in people with obesity or overweight and type 2 diabetes (ZUPREME‑2) and a planned combination study pairing petrelintide with Roche’s incretin agent CT‑388 are expected to clarify its role either as a stand‑alone amylin therapy or as part of fixed‑dose combinations within Roche’s cardiometabolic portfolio.

What is petrelintide mechanism of action and how does it act?

Mechanistically, petrelintide is designed as a long‑acting, chemically stable amylin analogue suitable for co‑formulation with other peptides; by activating amylin receptors it can enhance leptin sensitivity and promote earlier satiety, offering a differentiated, potentially GLP‑1‑comparable weight‑loss profile with improved gastrointestinal tolerability that could become an important complement to existing incretin‑based obesity treatments.

How Does Petrelintide’s Weight-Loss Efficacy Compare With Eloralintide?

• Initial high‑level data suggest that eloralintide may have greater weight‑loss efficacy than petrelintide.

• At their top tested doses, eloralintide led to about 20.1% mean weight loss at 48 weeks, whereas petrelintide produced up to 10.7% mean weight loss at 42 weeks versus 1.7% with placebo, with placebo-like tolerability.

What Does Roche and Zealand Pharma’s Deal on Petrelintide Mean for Metabolic Disease Treatments?

Roche and Zealand Pharma have entered a strategic collaboration to co-develop and co-commercialize petrelintide, a potential best-in-class amylin analogue, both as a monotherapy and in combination with Roche’s dual GLP‑1/GIP receptor agonist CT‑388. The partnership aims to enhance efficacy and tolerability in treating cardiovascular, renal, and metabolic (CVRM) diseases.

Under the agreement, Zealand will receive upfront and milestone payments totaling up to $5.3 billion, including $1.65 billion in initial payments and additional development and sales-based milestones. Profits and losses will be shared equally in the U.S. and Europe, where both companies will co-commercialize the therapy, while Roche holds exclusive rights elsewhere and will manage manufacturing and supply.

Zealand will also pay Roche $350 million, offsettable against milestones, for fixed-dose or next-generation combination products.